Technetium-99m labeled Ibuprofen: Development and biological evaluation using sterile inflammation induced animal models

  • Naeem-Ul-Haq Khan
  • Syed Ali Raza NaqviEmail author
  • Hamza Sohail
  • Samina RoohiEmail author
  • Muhammad Asghar Jamal
Original Article


In this study we are presenting the development of technetium-99m (99mTc) labeled ibuprofen for the imaging of aseptic inflammation. 99mTc-Ibuprofen complex was developed by optimizing the radiolabeling conditions such as reaction time, ligand and reducing agent concentration, pH, reaction time and temperature. Following the addition of 600 µg of ibuprofen, 4 µg of stannous chloride as reducing agent and 300 MBq 99mTc radioactivity; the pH of reaction mixture was adjusted to 11 and allowed to react for 15 min at room temperature. Chromatography analysis revealed > 94% 99mTc-ibuprofen complex formation with promising stability in saline and blood serum up to 6 h. Biodistribution study using normal and sterile inflammation induced mice indicated low accumulation of labeled compound in key body organs; however, kidneys (14.76 ± 0.87% ID/g organ) and bladder (31.6 ± 3.0% ID/g organ) showed comparatively higher radioactivity due to main excretory path. Inflamed to normal tissues ratio (T/NT), at 1 h post-injection, showed promising value (4.57 ± 0.56). The SPECT imaging of artificially inflammation induced rabbit model also verified the biodistribution results. In conclusion, radiochemical purity and biological evaluation of 99mTc-ibuprofen complex indicates the agent can be utilized for imaging of deep seated aseptic inflammation.


Radiopharmaceuticals Nuclear medicine Infection imaging Ibuprofen 99mTc-Ibuprofen 



The study is a part of HEC funded Project No. 5612/Punjab/NRPU/R&D/HEC/2016, thanks to HEC, GCU Faisalabad, and PINSTECH Islamabad for providing resources and platform to conduct this research.


This study was funded by Higher Education Commission (HEC), Islamabad, Pakistan under Grant No. 5612/Punjab/NRPU/R&D/HEC/2016.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The article is in compliance with ethical standards with approval from ethical review committee.

Informed consent

Informed consent was taken from all co-authors before submission of manuscript.


  1. 1.
    Martínez-Rodríguez I, Carril J (2013) Update on the use of PET radiopharmaceuticals in inflammatory disease. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 32:378–386Google Scholar
  2. 2.
    Kyprianidou P, Tsoukalas C, Chiotellis A, Papagiannopoulou D, Raptopoulou CP, Terzis A, Pelecanou M, Papadopoulos M, Pirmettis I (2011) First example of well-characterized Re and 99 m Tc tricarbonyl complexes of ciprofloxacin and norfloxacin in the development of infection-specific imaging agents. Inorg Chim Acta 370:236–242CrossRefGoogle Scholar
  3. 3.
    Rasheed R, Naqvi SAR, Gillani SJH, Zahoor AF, Jielani A, Saeed N (2017) 99 m) Tc-tazobactam, a novel infection imaging agent: radiosynthesis, quality control, biodistribution, and infection imaging studies. J Label Compd Radiopharm 60:242–249CrossRefGoogle Scholar
  4. 4.
    Motaleb MA, Ibrahem IT, Ayoub VR, Geneidi AS (2016) Preparation and biological evaluation of (99 m)Tc-ropinirole as a novel radiopharmaceutical for brain imaging. J Label Compd Radiopharm 59:147–152CrossRefGoogle Scholar
  5. 5.
    Fazli A, Salouti M, Ahmadi G, Mirshojaei SF, Mazidi M, Heidari Z (2012) Radiolabeling of ceftriaxone with 99 m Tc as a Targeting radiopharmaceutical for Staphylococcus aureus detection in mouse model. Iran J Med Phys 9:103–110Google Scholar
  6. 6.
    Chianelli M, Mather SJ, Martin-Comin J, Signore A (1997) Radiopharmaceuticals for the study of inflammatory processes: a review. Nucl Med Commun 18:437–455CrossRefGoogle Scholar
  7. 7.
    Larikka MJ, Ahonen AK, Niemela O, Junila JA, Hamalainen MM, Britton K, Syrjala HP (2002) Comparison of 99mTc ciprofloxacin, 99mTc white blood cell and three-phase bone imaging in the diagnosis of hip prosthesis infections: improved diagnostic accuracy with extended imaging time. Nucl Med Commun 23:655–661CrossRefGoogle Scholar
  8. 8.
    Asli IN, Javadi H, Seddigh H, Mogharrabi M, Hooman A, Ansari M, Jalallat S, Assadi M (2011) The diagnostic value of 99mTc-IgG scintigraphy in the diabetic foot and comparison with 99mTc-MDP scintigraphy. J Nucl Med Technol 39:226–230CrossRefGoogle Scholar
  9. 9.
    Hughes DK (2003) Nuclear medicine and infection detection: the relative effectiveness of imaging with 111In-oxine-, 99mTc-HMPAO-, and 99mTc-stannous fluoride colloid-labeled leukocytes and with 67 Ga-citrate. J Nucl Med Technol 31:196–201 (quiz 203–194)Google Scholar
  10. 10.
    Das SS, Hall AV, Wareham DW, Britton KE (2002) Infection imaging with radiopharmaceuticals in the 21st century. Braz Arch Biol Technol 45:25–37CrossRefGoogle Scholar
  11. 11.
    Britton K, Wareham D, Das S, Solanki K, Amaral H, Bhatnagar A, Katamihardja A, Malamitsi J, Moustafa H, Soroa V (2002) Imaging bacterial infection with 99mTc-ciprofloxacin (Infecton). J Clin Pathol 55:817–823CrossRefGoogle Scholar
  12. 12.
    Naqvi SAR, Drlica K (2017) Fluoroquinolones as imaging agents for bacterial infection. Dalton Trans (Cambridge, England: 2003). 46:14452–14460CrossRefGoogle Scholar
  13. 13.
    Naqvi SAR, Roohi S, Iqbal A (2018) Ciprofloxacin: from infection therapy to molecular imaging. Mol Biol Rep 45:1457–1468CrossRefGoogle Scholar
  14. 14.
    Sarda L, Crémieux A-C, Lebellec Y, Meulemans A, Lebtahi R, Hayem G, Génin R, Delahaye N, Huten D, Guludec L, D (2003) Inability of 99mTc-ciprofloxacin scintigraphy to discriminate between septic and sterile osteoarticular diseases. J Nucl Med 44:920–926Google Scholar
  15. 15.
    Whittle B (2000) COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors. Gut 47:320–325CrossRefGoogle Scholar
  16. 16.
    Yadav MR, Pawar VP, Marvaniya SM, Halen PK, Giridhar R, Mishra AK (2008) Site specific chemical delivery of NSAIDs to inflamed joints: Synthesis, Biological activity and γ-imaging studies of quaternary ammonium salts of tropinol esters of some NSAIDs or their active metabolites. Bioorganic Med Chem 16:9443–9449CrossRefGoogle Scholar
  17. 17.
    Iqbal A, Naqvi SAR (2018) Radiosynthesis and Biodistribution of (99 m)Tc-Metronidazole as an Escherichia coli Infection. Imaging Radiopharm 185:127–139Google Scholar
  18. 18.
    Berry DJ, Torres M, de Rosales R, Charoenphun P, Blower PJ (2012) Dithiocarbamate complexes as radiopharmaceuticals for medical imaging. Mini Rev Med Chem 12:1174–1183CrossRefGoogle Scholar
  19. 19.
    Motaleb MA, Ibrahem IT, Ayoub VR, Geneidi AS (2016) Preparation and biological evaluation of 99mTc–ropinirole as a novel radiopharmaceutical for brain imaging. J Label Compd Radiopharm 59:147–152CrossRefGoogle Scholar
  20. 20.
    Ettinger M, Calliess T, Kielstein JT, Sibai J, Brückner T, Lichtinghagen R, Windhagen H, Lukasz A (2015) Circulating biomarkers for discrimination between aseptic joint failure, low-grade infection, and high-grade septic failure. Clin Infect Dis 61:332–341CrossRefGoogle Scholar
  21. 21.
    Bushra R, Aslam N (2010) An overview of clinical pharmacology of Ibuprofen. Oman Med J 25:155–1661Google Scholar
  22. 22.
    Lambrecht FY (2011) Evaluation of 99 m Tc-labeled antibiotics for infection detection. Ann Nucl Med 25:1–6CrossRefGoogle Scholar
  23. 23.
    Shahnazarian V, Ramai D, Reddy M (2018) A rare case of ibuprofen-induced acute liver injury. Cureus 10:e3225Google Scholar
  24. 24.
    Welling MM, Paulusma-Annema A, Balter HS, Pauwels EK, Nibbering PH (2000) Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations. Eur J Nucl Med 27:292–301CrossRefGoogle Scholar
  25. 25.
    Welling M, Feitsma HI, Calame W, Pauwels EK (1997) Detection of experimental infections with 99mTc-labeled monoclonal antibodies against TNF-α and interleukin-8. Nucl Med Biol 24:649–655CrossRefGoogle Scholar
  26. 26.
    Chianelli M, Signore A, Ronga G, Fritzberg A, Mather S (1994) Labeling, purification and biodistribution of 99 m Tc-interleukin-2: a new radiopharmaceutical for in vivo detection of activated lymphocytes. Eur J Nucl Med 21:807Google Scholar
  27. 27.
    Welling M, Feitsma H, Calame W, Pauwels E (1997) Localization of a bacterial infection with 99Tcm-labelled human IgG: further improvement with enriched IgG subclass preparations. Nucl Med Commun 18:1057–1064CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Department of ChemistryGovernment College University FaisalabadFaisalabadPakistan
  2. 2.Islamabad Medical and Dental CollegeMurree RoadPakistan
  3. 3.Isotope Production Devision (IPD)Pakistan Institute of Nuclear Science and Technology (PINSTECH)NilorePakistan

Personalised recommendations